blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3165220

EP3165220 - PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-NUCLEATING AGENT [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  11.10.2024
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  01.03.2019
FormerGrant of patent is intended
Status updated on  17.12.2018
FormerExamination is in progress
Status updated on  13.11.2018
FormerGrant of patent is intended
Status updated on  09.10.2018
FormerExamination is in progress
Status updated on  02.03.2018
FormerRequest for examination was made
Status updated on  17.11.2017
FormerThe application has been published
Status updated on  07.04.2017
Most recent event   Tooltip11.10.2024Patent maintained (B2 publication)published on 13.11.2024  [2024/46]
Applicant(s)For all designated states
Merck Sharp & Dohme LLC
126 East Lincoln Avenue
Rahway, New Jersey 07065 / US
[2022/42]
Former [2017/19]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Inventor(s)01 / ARTINO, Laura, M.
126 East Lincoln Avenue
Rahway, NJ New Jersey 07065-0907 / US
02 / CRUANES, Maria, T.
126 East Lincoln Avenue
Rahway, NJ New Jersey 07065-0907 / US
03 / XU, Wei
126 East Lincoln Avenue
Rahway, NJ New Jersey 07065-0907 / US
04 / ZHU, Honggang
126 East Lincoln Avenue
Rahway, NJ New Jersey 07065-0907 / US
 [2017/19]
Representative(s)Merck Sharp & Dohme LLC
120 Moorgate
London EC2M 6UR / GB
[2024/46]
Former [2017/19]Jaap, David Robert
Merck Sharp & Dohme Corp.
European Patent Department
Hertford Road
Hoddesdon, Hertfordshire EN11 9BU / GB
Application number, filing date16198994.202.12.2005
[2017/19]
Priority number, dateUS20040632859P03.12.2004         Original published format: US 632859 P
[2017/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3165220
Date:10.05.2017
Language:EN
[2017/19]
Type: B1 Patent specification 
No.:EP3165220
Date:03.04.2019
Language:EN
[2019/14]
Type: B2 New European patent specification 
No.:EP3165220
Date:13.11.2024
Language:EN
[2024/46]
Search report(s)(Supplementary) European search report - dispatched on:EP22.03.2017
ClassificationIPC:A61K9/20, A61K9/48, A61K31/513
[2017/19]
CPC:
A61K31/513 (EP,US); A61K9/2009 (EP,US); A61K9/2013 (EP,US);
A61K9/2018 (EP,US); A61K9/2054 (EP,US); A61P31/18 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/51]
Former [2017/19]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT ANTI-KEIMBILDNER[2017/19]
English:PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-NUCLEATING AGENT[2017/19]
French:COMPOSITION PHARMACEUTIQUE CONTENANT UN AGENT D'ANTI-NUCLÉATION[2017/19]
Examination procedure15.11.2016Date on which the examining division has become responsible
08.11.2017Amendment by applicant (claims and/or description)
10.11.2017Examination requested  [2017/51]
28.02.2018Despatch of a communication from the examining division (Time limit: M06)
05.09.2018Reply to a communication from the examining division
10.10.2018Communication of intention to grant the patent
15.02.2019Fee for grant paid
15.02.2019Fee for publishing/printing paid
15.02.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP05852790.4  / EP1819323
Opposition(s)Opponent(s)01  17.12.2019  19.12.2019  ADMISSIBLE
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 02  03.01.2020  07.01.2020  ADMISSIBLE
Ter Meer Steinmeister & Partner Patentanwälte mbB
Nymphenburger Strasse 4
80335 München / DE
 [2024/08]
Former [2024/04]
Opponent(s)01  17.12.2019  19.12.2019  ADMISSIBLE
Kraus & Weisert Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Opponent's representative
Kraus & Weisert Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 02  03.01.2020  07.01.2020  ADMISSIBLE
Ter Meer Steinmeister & Partner Patentanwälte mbB
Nymphenburger Strasse 4
80335 München / DE
Former [2020/07]
Opponent(s)01  17.12.2019  19.12.2019  ADMISSIBLE
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstr. 2
80538 München / DE
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 02  03.01.2020  07.01.2020  ADMISSIBLE
Ter Meer Steinmeister & Partner Patentanwälte mbB
Nymphenburger Strasse 4
80335 München / DE
Former [2020/04]
Opponent(s)01  17.12.2019  19.12.2019  ADMISSIBLE
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstr. 2
80538 München / DE
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
17.01.2020Invitation to proprietor to file observations on the notice of opposition
02.06.2020Reply of patent proprietor to notice(s) of opposition
02.06.2021Date of oral proceedings
19.11.2021Despatch of interlocutory decision in opposition
19.11.2021Despatch of minutes of oral proceedings
26.03.2024Legal effect of interlocutory decision in opposition
17.07.2024Despatch of communication that the patent will be maintained as amended
Appeal following opposition26.01.2022Appeal received No.  T0091/22
26.01.2022Payment of appeal fee
29.03.2022Statement of grounds filed
26.03.2024Result of appeal procedure: appeal of the proprietor was rejected
14.06.2024Despatch of the decision of the Board of Appeal
11.01.2022Appeal received No.  T0091/22
11.01.2022Payment of appeal fee
22.03.2022Statement of grounds filed
26.03.2024Result of appeal procedure: appeal of the proprietor was rejected
14.06.2024Despatch of the decision of the Board of Appeal
26.03.2024Date of oral proceedings
Fees paidRenewal fee
15.03.2017Renewal fee patent year 03
15.03.2017Renewal fee patent year 04
15.03.2017Renewal fee patent year 05
15.03.2017Renewal fee patent year 06
15.03.2017Renewal fee patent year 07
15.03.2017Renewal fee patent year 08
15.03.2017Renewal fee patent year 09
15.03.2017Renewal fee patent year 10
15.03.2017Renewal fee patent year 11
15.03.2017Renewal fee patent year 12
08.12.2017Renewal fee patent year 13
10.12.2018Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.12.2005
AT03.04.2019
CY03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
IE02.12.2019
LU02.12.2019
BE31.12.2019
[2021/32]
Former [2021/26]AT03.04.2019
CY03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
IE02.12.2019
LU02.12.2019
BE31.12.2019
Former [2020/51]AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
IE02.12.2019
LU02.12.2019
BE31.12.2019
Former [2020/46]AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
IE02.12.2019
LU02.12.2019
Former [2020/39]AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/26]AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/11]AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
SK03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/10]AT03.04.2019
CZ03.04.2019
DK03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
PL03.04.2019
RO03.04.2019
SE03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/09]AT03.04.2019
CZ03.04.2019
DK03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
PL03.04.2019
SE03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/04]AT03.04.2019
CZ03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
PL03.04.2019
SE03.04.2019
BG03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/03]AT03.04.2019
CZ03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
PL03.04.2019
SE03.04.2019
BG03.07.2019
GR04.07.2019
PT03.08.2019
Former [2019/52]CZ03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
PL03.04.2019
SE03.04.2019
BG03.07.2019
GR04.07.2019
PT03.08.2019
Former [2019/51]CZ03.04.2019
FI03.04.2019
LT03.04.2019
LV03.04.2019
SE03.04.2019
BG03.07.2019
GR04.07.2019
PT03.08.2019
Former [2019/49]CZ03.04.2019
FI03.04.2019
LT03.04.2019
SE03.04.2019
PT03.08.2019
Former [2019/48]FI03.04.2019
LT03.04.2019
SE03.04.2019
PT03.08.2019
Former [2019/47]FI03.04.2019
LT03.04.2019
Documents cited:Search[A] WO0185700  (JANSSEN PHARMACEUTICA NV et al.)
 [A] US2004002485  (FUJISHITA TOSHIO et al.)
 [E] WO2006060711  (MERCK & CO INC et al.)
 [E] WO2006060712  (MERCK & CO INC et al.)
 [A] US6369094  (BENTLEY ARTHUR et al.)
 [AD] WO03035077  (ANGELETTI P IST RICHERCHE BIO et al.)
by applicantWO03035077
   HAZUDA ET AL., J. VIROL., vol. 71, 1997, pages 7005 - 7011
   VACCA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 4096 - 4100
   "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO., pages: 1665 - 1675
   "Remington's Pharmaceutical Sciences", 1990
OppositionWO03035077
 WO2006060681
 WO03035077
 EP1904067
 WO2012147101
 WO03086319
 WO2006060681
 EP1904067
 WO2012147101
 WO03086319
 WO2006060730
   GUO ET AL.: "Pharmaceutical applications of naturally occurring water-soluble polymers", PHARM. SC. TECH. TODAY, vol. 1, no. 6, 1998, pages 254 - 261, XP055662415

DOI:   http://dx.doi.org/10.1016/S1461-5347(98)00072-8
   GAO ET AL.: "Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations", DRUG DEV. IND. PHARM., vol. 30, no. 2, 2004, pages 221 - 229, XP009115351

DOI:   http://dx.doi.org/10.1081/DDC-120028718
   USUI ET AL.: "Inhibitory effects of water-soluble polymers on precipitation of RS-8359", INT. J. PHARM., vol. 154, 1997, pages 59 - 66, XP008102782

DOI:   http://dx.doi.org/10.1016/S0378-5173(97)00129-4
   RAGHAVAN ET AL.: "Crystallization of hydrocortisone acetate: influence of polymers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 212, 2001, pages 213 - 221, XP007915168

DOI:   http://dx.doi.org/10.1016/S0378-5173(00)00610-4
   BAVIN: "Polymorphism in Process Development", CHEMISTRY & INDUSTRY, 21 August 1989 (1989-08-21), pages 527 - 529, XP001180136
   "Polymorphism_( materials_ science", WIKIPEDIA, 18 October 2019 (2019-10-18), XP055662425
   "Pharmaceutics, The Science of Dosage Form Design", 2002, article M. E. AULTON: "Chapter 20 - Modified-release peroral dosage forms", pages: 289 - 305, XP055298170
   LEUNER ET AL.: "Improving drug solubility for oral delivery using solid dispersion", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 50, 2000, pages 47 - 60, XP004257179, DOI: 10.1016/S0939-6411(00)00076-X

DOI:   http://dx.doi.org/10.1016/S0939-6411(00)00076-X
   USUI ET AL.: "Inhibitory effect of water-soluble polymers on precipitation of RS- 8359", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 154, 1997, pages 59 - 66, XP008102782, DOI: 10.1016/S0378-5173(97)00129-4

DOI:   http://dx.doi.org/10.1016/S0378-5173(97)00129-4
   GAO ET AL.: "Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 30, no. 2, 2004, pages 221 - 229, XP009115351

DOI:   http://dx.doi.org/10.1081/DDC-120028718
   RAGHAVAN S.L.: "Crystallisation of hydrocortisone acetate: influence of polymers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 212, 2001, pages 213 - 221, XP007915168, DOI: 10.1016/S0378-5173(00)00610-4

DOI:   http://dx.doi.org/10.1016/S0378-5173(00)00610-4
   GUO ET AL.: "Pharmaceutical applications of naturally occurring water-soluble polymers", PHARM. SC. TECH. TODAY, vol. 1, no. 6, 1998, pages 254 - 261
   GAO ET AL.: "Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations", DRUG DEV. IND. PHARM., vol. 30, no. 2, 2004, pages 221 - 229
   USUI ET AL.: "Inhibitory effects of water-soluble polymers on precipitation of RS-8359", INT. J. PHARM., vol. 154, 1997, pages 59 - 66
   RAGHAVAN ET AL.: "Crystallization of hydrocortisone acetate: influence of polymers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 212, 2001, pages 213 - 221
   BAVIN: "Polymorphism in Process Development", CHEMISTRY & INDUSTRY, 21 August 1989 (1989-08-21), pages 527 - 529
   "Pharmaceutics, The Science of Dosage Form Design", 2002, article M. E. AULTON: "Chapter 20 - Modified-release peroral dosage forms", pages: 289 - 305
   LEUNER ET AL.: "Improving drug solubility for oral delivery using solid dispersion", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 50, 2000, pages 47 - 60, DOI: 10.1016/S0939-6411(00)00076-X
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.